NCT02568683 - Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 11, 2016

Primary Completion Date

October 3, 2016

Study Completion Date

June 22, 2017

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG

Entospletinib

ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state

DRUG

Vincristine

VCR administered intravenously

Trial Locations (7)

Forrest General Hospital, Hattiesburg

Medical University of South Carolina, Charleston

Groupe Hospitalier du Haut Leveque, Pessac

Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille), Lille

Institut Paoli Calmettes, Marseille

Centre Hospitalier Universitaire de Dijon Hôpital du Bocage, Dijon

Centre Hospital Lyon Sud, Pierre-Bénite